IRE1A Antibody

What is IRE1α and why is it important in cellular research?

IRE1α (Inositol-requiring enzyme 1 alpha) is a serine/threonine kinase that functions as one of the three primary branches of the Unfolded Protein Response (UPR) signaling pathway. It is activated in response to endoplasmic reticulum (ER) stress conditions . As both a protein kinase and an atypical site-specific RNase, IRE1α plays a critical role in mediating cellular responses to ER stress . IRE1α exists as a constitutive homodimer under normal conditions and assembles into small oligomers upon ER stress . Its importance in research stems from its dual enzymatic capabilities and its involvement in various pathological conditions, including cancer, neurodegenerative diseases, and inflammatory disorders .

How does IRE1α function in the Unfolded Protein Response?

When ER stress occurs, IRE1α undergoes conformational changes leading to its activation. The activated IRE1α performs two primary functions:

• XBP1 mRNA splicing: IRE1α's RNase activity removes a 26-nucleotide intron from XBP1 mRNA, resulting in the production of XBP1s (spliced) protein, which activates the transcription of numerous pro-survival genes .

• RIDD (Regulated IRE1-Dependent Decay): IRE1α degrades specific mRNA targets such as DGAT2, BCAM, and TGOLN2, which helps alleviate ER stress .

The activation process begins with dimerization of IRE1α's lumenal domains, followed by trans-autophosphorylation of cytosolic kinase domains, which ultimately activates its RNase function. This cascade plays a crucial role in determining cell fate decisions between survival and apoptosis under ER stress conditions .

What are the key structural domains of IRE1α that antibodies typically target?

IRE1α contains several distinct domains that antibodies may target:

• Lumenal domain: Contains the ER stress-sensing region with important interfaces (IF1L and IF2L) involved in dimerization and oligomerization .

• Transmembrane domain: Anchors the protein to the ER membrane.

• Cytosolic kinase domain: Responsible for trans-autophosphorylation activities.

• RNase domain: Contains the catalytic site responsible for XBP1 splicing and RIDD activity .

Antibodies are typically generated against epitopes in the cytosolic domains (kinase and RNase) as they are more accessible, or against phosphorylated residues to detect the activated form of IRE1α. Some antibodies target the lumenal domain for studying IRE1α's stress-sensing mechanisms .

How can I effectively validate the specificity of an IRE1α antibody?

Validating IRE1α antibody specificity requires a multi-faceted approach:

• CRISPR/Cas9 knockout controls: Generate IRE1α knockout cell lines (targeting the ERN1 gene) to serve as negative controls. The absence of signal in these cells confirms antibody specificity .

• siRNA knockdown verification: Use siRNA to silence ERN1 expression and confirm reduced antibody signal proportional to the knockdown efficiency .

• Phosphorylation-specific validation: For phospho-specific antibodies, treat with phosphatase to demonstrate signal loss, or use phospho-null mutants (e.g., replacing serine/threonine with alanine) .

• Immunoblotting profile analysis: IRE1α typically appears as a band around 110-130 kDa, with a mobility shift upon phosphorylation. Verify that the antibody detects this characteristic pattern .

• Induction experiments: Treat cells with established ER stress inducers like tunicamycin (Tm) and verify increased phosphorylation and/or total IRE1α signal .

What are optimal conditions for detecting IRE1α by Western blotting?

For optimal Western blotting results with IRE1α antibodies:

• Sample preparation: Use RIPA buffer supplemented with phosphatase inhibitors (especially important for detecting phosphorylated IRE1α) and protease inhibitors. Include 1-2 mM EDTA to prevent metalloprotease activity.

• Gel percentage and transfer: Use 8-10% SDS-PAGE gels for better resolution of IRE1α (~110 kDa). Transfer to PVDF membranes (rather than nitrocellulose) at lower voltage (30V) overnight at 4°C for more efficient transfer of this high molecular weight protein.

• Blocking conditions: Block with 5% BSA in TBST rather than milk when detecting phospho-IRE1α, as milk contains phospho-proteins that may interfere with detection.

• Antibody dilution and incubation: Primary antibodies typically work optimally at 1:1000 dilution in 5% BSA/TBST with overnight incubation at 4°C with gentle rocking.

• Positive controls: Include cells treated with tunicamycin (5 µg/mL for 4-6 hours) as a positive control to ensure the antibody can detect the activated/phosphorylated form of IRE1α .

How do I troubleshoot weak or non-specific signals when using IRE1α antibodies?

When encountering issues with IRE1α antibody signals:

• Low signal intensity:

  • Increase protein loading (50-80 μg recommended for endogenous IRE1α)

  • Extend primary antibody incubation time to 48 hours at 4°C

  • Use enhanced chemiluminescence (ECL) reagents with higher sensitivity

  • Confirm IRE1α expression in your cell type, as expression levels vary significantly across different tissues and cell lines

• Non-specific bands:

  • Increase washing duration and number of washes (5-6 washes of 10 minutes each)

  • Optimize antibody dilution through titration experiments

  • Try alternative blocking reagents (BSA vs. milk vs. commercial blocking buffers)

  • Use IRE1α knockout cells as negative controls to identify which bands are specific

• Background issues:

  • Add 0.05-0.1% SDS to washing buffer to reduce non-specific binding

  • Pre-absorb antibody with cell lysate from IRE1α knockout cells

  • Consider alternative antibody clones if persistent problems occur

How can I distinguish between monomeric, dimeric, and oligomeric forms of IRE1α?

Distinguishing between different oligomeric states of IRE1α requires specialized techniques:

• Native PAGE analysis: Use non-denaturing conditions to preserve protein complexes, followed by immunoblotting with IRE1α antibodies. Different oligomeric states will migrate at distinct molecular weights.

• Chemical crosslinking: Apply membrane-permeable crosslinkers like disuccinimidyl suberate (DSS) to cells prior to lysis, then perform standard SDS-PAGE and immunoblotting to visualize crosslinked oligomers .

• Fluorescence microscopy techniques: Create cells expressing IRE1α-fluorescent protein fusions (e.g., IRE1α-HaloTag or IRE1α-mEGFP) and employ techniques such as:

  • Fluorescence recovery after photobleaching (FRAP)

  • Single-molecule tracking to analyze diffusion coefficients (slower diffusion indicates larger oligomeric complexes)

  • Fluorescence correlation spectroscopy (FCS)

• Density gradient centrifugation: Fractionate cell lysates on sucrose or glycerol gradients to separate protein complexes by size, then analyze fractions by immunoblotting.

For research requiring precise quantification of oligomeric states, trajectory analysis of IRE1α-HaloTag diffusion has been demonstrated to clearly distinguish between dimeric and higher-order oligomeric forms in response to ER stress induction .

What are the best methods for detecting IRE1α phosphorylation status?

Detecting IRE1α phosphorylation status can be accomplished through several approaches:

• Phospho-specific antibodies: Use antibodies specifically recognizing phosphorylated residues on IRE1α. This provides direct visualization of activation status in immunoblotting or immunofluorescence applications .

• Mobility shift assays: Phosphorylation adds negative charges and increases molecular weight, causing IRE1α to migrate more slowly on SDS-PAGE. This can be observed even with antibodies against total IRE1α .

• Phos-tag™ SDS-PAGE: This specialized acrylamide gel containing Phos-tag™ molecules specifically retards the migration of phosphorylated proteins, providing enhanced resolution of different phosphorylation states.

• Mass spectrometry analysis: For comprehensive mapping of phosphorylation sites, immunoprecipitate IRE1α and analyze by LC-MS/MS.

• Functional readouts: Indirect assessment via measurement of XBP1 splicing using RT-PCR or qPCR as a surrogate marker for IRE1α activation .

When employing phospho-specific antibodies, always include appropriate controls such as lambda phosphatase-treated samples and cells treated with IRE1α kinase inhibitors to validate specificity .

How can I assess IRE1α RNase activity in cellular and biochemical assays?

Several methods are available to assess IRE1α RNase activity:

• XBP1 splicing assay: The most common approach involves RT-PCR to detect unspliced and spliced XBP1 mRNA forms. Primers flanking the splice junction will generate different sized products for unspliced (XBP1u) and spliced (XBP1s) forms .

• XBP1s reporter systems: Fluorescent or luminescent reporters designed to express only when XBP1 splicing occurs provide a quantitative readout of IRE1α RNase activity.

• RIDD substrate analysis: Measure levels of known RIDD targets (DGAT2, BCAM, TGOLN2) by qRT-PCR to assess degradation mediated by IRE1α RNase activity .

• In vitro RNase assays: Using purified IRE1α protein or immunoprecipitated IRE1α complexes, incubate with fluorescently labeled RNA substrates and measure cleavage products.

• Inhibitor studies: Use specific IRE1α RNase inhibitors like 4μ8C or HM100168 as controls to confirm that observed RNA processing is specifically mediated by IRE1α .

When designing experiments to assess RNase activity, remember that IRE1α inhibitors may affect different aspects of its function. For example, 4μ8C specifically targets the RNase domain without affecting kinase activity, while HM100168 is another potent and selective IRE1α RNase inhibitor .

How can IRE1α antibodies be used to study its role in cancer progression?

IRE1α antibodies are instrumental in cancer research through several applications:

• Expression profiling: Immunohistochemistry (IHC) on tumor microarrays or patient samples can assess IRE1α expression levels across different cancer types and stages. Studies have shown increased IRE1α signaling in prostate cancer and other malignancies .

• Phosphorylation status: Phospho-specific antibodies help evaluate IRE1α activation in tumors, revealing whether the UPR is chronically activated in specific cancer subtypes .

• Co-culture systems: Antibodies enable monitoring of IRE1α activation in complex tumor microenvironment models. For instance, studies have revealed that tumor cells can induce IRE1α activation in hepatic stellate cells, contributing to tumor progression .

• Treatment response biomarkers: Changes in IRE1α phosphorylation or oligomerization after treatment with chemotherapeutics or targeted therapies may predict response efficacy.

• Tumor microenvironment analysis: Multiplex immunofluorescence combining IRE1α antibodies with markers for immune cells or stromal components reveals how IRE1α signaling affects tumor-associated macrophages and other TME components .

When designing cancer-related studies using IRE1α antibodies, consider the cell-line-specific differences in IRE1α inhibition responses, as observed in studies comparing HepG2 and Huh7 cells, where silencing IRE1α led to opposite effects on cell proliferation .

What approaches can be used to study IRE1α-dependent signaling in immune cells?

Studying IRE1α in immune cells requires specialized approaches:

• Flow cytometry: Intracellular staining with IRE1α antibodies allows assessment of expression and activation status across immune cell subpopulations. Phospho-flow techniques can detect activated IRE1α in specific immune cell types.

• Single-cell analysis: Combined with transcript profiling, IRE1α antibody staining can reveal heterogeneity in UPR activation within immune populations.

• Functional readouts: Measure XBP1 splicing and downstream gene expression to assess IRE1α activity during immune cell development, activation, and differentiation.

• Genetic models: Use conditional knockout models targeting ERN1 in specific immune cell lineages as crucial controls for antibody specificity .

• Tumor immunology applications: IRE1α signaling affects anti-tumor immunity in the tumor microenvironment. Antibodies can help track how IRE1α inhibition reprograms tumor-associated macrophages and enhances responses to immunotherapy like anti-PD-1 treatment .

Research has shown that IRE1α signaling not only promotes cancer cell growth and survival but also interferes with anti-tumor immunity in the tumor microenvironment, making it an important target for combined approaches with immunotherapy .

How should IRE1α antibodies be optimized for detecting stress responses in neurological disease models?

Optimizing IRE1α antibody protocols for neurological disease research requires specific considerations:

• Tissue preparation: For brain samples, use shorter fixation times (4-8 hours) with 4% PFA to preserve epitope accessibility while maintaining tissue architecture. For immunofluorescence microscopy, consider using thinner sections (5-10 μm) to improve antibody penetration.

• Antigen retrieval methods: For formalin-fixed paraffin-embedded (FFPE) brain tissue, citrate buffer (pH 6.0) heat-induced epitope retrieval works best for most IRE1α antibodies. Extend retrieval times to 30 minutes for better results.

• Background reduction: Brain tissue often exhibits high background; use Sudan Black B (0.1% in 70% ethanol) post-staining to reduce lipofuscin autofluorescence when performing fluorescence microscopy.

• Cell-type specific analysis: Combine IRE1α antibodies with neuronal, glial, or microglial markers in multiplex immunofluorescence to identify which cell types activate the UPR in disease contexts.

• In vivo models: When using mouse models of neurodegenerative diseases, consider tissue clearing techniques (CLARITY, iDISCO+) combined with IRE1α antibody staining for 3D visualization of UPR activation patterns throughout brain regions .

Remember that ER stress activation has been confirmed in various neurodegenerative conditions, making IRE1α detection a valuable approach for understanding disease mechanisms and developing potential therapeutic interventions .

What controls should be included when validating results with IRE1α antibodies?

Comprehensive experimental validation requires several controls:

• Positive controls:

  • Cell lines with known high IRE1α expression (e.g., pancreatic β-cells, plasma cells)

  • Cells treated with ER stress inducers like tunicamycin (5 μg/mL), thapsigargin (1 μM), or DTT (2 mM) for 4-6 hours

  • Cell lines overexpressing IRE1α via inducible expression systems

• Negative controls:

  • CRISPR/Cas9-generated IRE1α knockout cells or tissues from knockout models

  • siRNA-mediated IRE1α knockdown samples

  • Primary cells known to express minimal IRE1α

• Specificity controls:

  • Pre-adsorption of antibody with immunizing peptide

  • Multiple antibodies targeting different epitopes of IRE1α to confirm concordant results

  • Mutant forms of IRE1α with altered key residues (K121Y, WLLI 359-362-GSGS) to validate domain-specific antibodies

• Activity controls:

  • IRE1α inhibitors: 4μ8C (RNase inhibitor) or kinase inhibitors to confirm functional significance of observed signals

  • XBP1 splicing analysis as functional readout of IRE1α activity

How can I optimize immunoprecipitation protocols for studying IRE1α protein interactions?

Optimizing immunoprecipitation (IP) for IRE1α:

• Lysis buffer composition:

  • Use milder lysis buffers (1% NP-40 or 0.3% CHAPS) instead of RIPA to preserve protein-protein interactions

  • Include phosphatase inhibitors (10 mM sodium fluoride, 2 mM sodium orthovanadate)

  • Add protease inhibitors and 1 mM EDTA to prevent degradation

  • Consider including chemical crosslinkers to stabilize transient interactions

• Pre-clearing step:

  • Pre-clear lysates with Protein A/G beads for 1 hour at 4°C to reduce non-specific binding

  • Filter lysates through a 0.45 μm filter to remove aggregates

• Antibody selection and coupling:

  • Test multiple IRE1α antibodies targeting different epitopes

  • For weak interactions, covalently couple antibodies to beads using dimethyl pimelimidate (DMP)

  • Use 2-5 μg of antibody per mg of total protein

• Washing conditions:

  • Use gentle washing conditions (TBS with 0.1% detergent) for initial washes

  • Increase stringency in later washes if background is high

  • Keep samples at 4°C throughout to preserve interactions

• Elution strategies:

  • For non-covalently bound antibodies, use SDS sample buffer at room temperature instead of boiling

  • For native complex analysis, consider elution with excess immunizing peptide

When studying IRE1α oligomerization, consider using cross-linking agents like disuccinimidyl suberate (DSS) before lysis to stabilize protein complexes .

What are the best methods for visualizing IRE1α localization and dynamics in living cells?

For visualizing IRE1α in living cells:

• Fluorescent protein tagging:

  • C-terminal tags are preferable as they interfere less with IRE1α function

  • HaloTag fusion proteins have proven effective for IRE1α visualization without disrupting function

  • mEGFP tagging has been successfully used in tunable expression systems

  • Validate tagged constructs by confirming their ability to splice XBP1 and respond to ER stress

• Live-cell imaging techniques:

  • Single-particle tracking to analyze diffusion coefficients and oligomerization states

  • FRAP (Fluorescence Recovery After Photobleaching) to measure IRE1α mobility

  • Total Internal Reflection Fluorescence (TIRF) microscopy for high-resolution imaging of IRE1α clusters

  • Lattice light-sheet microscopy for 3D visualization with minimal phototoxicity

• Expression level considerations:

  • Use inducible promoters (TetON system) to control expression levels and avoid artifacts from overexpression

  • Aim for expression levels close to endogenous (within 5-fold) when possible

  • Create stable cell lines rather than using transient transfection for more consistent results

• Visualization of activation dynamics:

  • Design FRET-based reporters that detect IRE1α conformational changes

  • Use split fluorescent proteins to visualize IRE1α oligomerization

  • Combine with orthogonal markers for ER stress or UPR activation

CRISPR/Cas9 gene editing to tag endogenous IRE1α with fluorescent proteins provides the most physiologically relevant system, as demonstrated in cell lines where endogenous IRE1α was tagged with HaloTag .

How should I quantify and interpret changes in IRE1α phosphorylation levels?

Proper quantification and interpretation of IRE1α phosphorylation requires:

• Normalization approaches:

  • Always normalize phospho-IRE1α signal to total IRE1α levels, not to housekeeping proteins

  • When using phospho-specific antibodies, confirm results with mobility shift assays using total IRE1α antibodies

  • Use densitometric analysis with appropriate software (ImageJ, Image Studio) for quantification

• Time-course considerations:

  • IRE1α phosphorylation typically peaks between 4-8 hours after ER stress induction

  • Include multiple time points to capture the dynamic nature of phosphorylation

  • Remember that prolonged ER stress can lead to adaptation and decreased phosphorylation despite continued stress

• Statistical analysis:

  • Perform experiments in biological triplicates at minimum

  • Use appropriate statistical tests (t-test for simple comparisons, ANOVA for multiple conditions)

  • Consider using phosphorylation kinetics (rate of change) rather than endpoint measurements for more meaningful comparisons

• Interpretation guidelines:

  • Increased phosphorylation doesn't always correlate linearly with increased RNase activity

  • Different phosphorylation sites may have distinct functional consequences

  • Consider the cellular context—basal phosphorylation levels vary significantly between cell types

What approaches can resolve contradictory results when studying IRE1α activation?

Resolving contradictory results in IRE1α research:

• Cell line considerations:

  • Different cell lines may show opposite responses to IRE1α inhibition, as observed with HepG2 and Huh7 cells

  • Validate findings across multiple cell lines representative of your tissue of interest

  • Consider the genetic background of your model systems (mutations in UPR components)

• Activation readout discrepancies:

  • When phosphorylation and XBP1 splicing data disagree, measure both parameters in parallel

  • Assess RIDD activity alongside XBP1 splicing, as these functions can be differentially regulated

  • Consider measuring reactive oxygen species (ROS) levels, as IRE1α activity affects ROS generation in a cell-line dependent manner

• Experimental timeline issues:

  • Temporal dynamics of IRE1α activation may differ between cell types

  • Use finer time-point resolution (e.g., every 30 minutes) during the first 8 hours post-stimulation

  • Consider pulsatile or oscillatory activation patterns that might be missed with limited sampling

• Technical reconciliation approaches:

  • Use multiple antibodies targeting different epitopes to confirm results

  • Employ orthogonal techniques (e.g., mass spectrometry) to validate phosphorylation status

  • Combine genetic approaches (knockdown/knockout) with pharmacological inhibition studies

Remember that IRE1α has complex regulatory mechanisms, and differences in experimental outcomes may reflect biological realities rather than technical artifacts .

How can I determine if changes in IRE1α activity are causative or reactive in disease models?

Establishing causality in IRE1α research requires:

• Temporal profiling:

  • Map the sequence of events by collecting samples at multiple timepoints

  • Determine whether IRE1α activation precedes or follows other disease markers

  • Use inducible systems to activate IRE1α at defined timepoints and observe downstream effects

• Genetic manipulation approaches:

  • Use CRISPR/Cas9 to generate IRE1α knockout models and observe effects on disease progression

  • Create knock-in models with constitutively active or dominant-negative IRE1α mutants

  • Employ inducible IRE1α expression systems with different expression levels to establish dose-response relationships

• Pharmacological interventions:

  • Use specific IRE1α inhibitors like 4μ8C or HM100168 at different disease stages

  • Compare results from RNase-specific inhibitors versus kinase inhibitors to dissect pathway contributions

  • Design rescue experiments where IRE1α activity is restored after inhibition

• Clinical correlation analyses:

  • Correlate IRE1α activation markers with disease progression in patient samples

  • Perform multivariate analyses to control for confounding factors

  • Stratify patients based on IRE1α activation levels and compare outcomes

• Mechanistic validation:

  • Identify and validate downstream effectors of IRE1α signaling relevant to your disease model

  • Determine whether preventing IRE1α activation also prevents these downstream effects

  • Use genetic complementation with IRE1α mutants to pinpoint which function (kinase vs. RNase) is causative

In mouse models of hepatocellular carcinoma, IRE1α inhibition with 4μ8C decreased tumor burden, providing evidence for a causative role of IRE1α signaling in this cancer type .

What emerging techniques might enhance the study of IRE1α localization and dynamics?

Emerging techniques for IRE1α research include:

• Super-resolution microscopy approaches:

  • STED (Stimulated Emission Depletion) microscopy for visualizing IRE1α clusters at nanoscale resolution

  • STORM/PALM techniques to map the precise organization of IRE1α oligomers

  • Expansion microscopy to physically enlarge samples for enhanced visualization of IRE1α structures

• Proximity labeling technologies:

  • APEX2 or TurboID fusions with IRE1α to identify proximal proteins in different activation states

  • Split-BioID systems to specifically label proteins interacting with oligomerized IRE1α

  • Integration with mass spectrometry for unbiased identification of the IRE1α interactome

• Live-cell biosensors:

  • FRET-based sensors to monitor IRE1α conformational changes in real-time

  • Fluorescent RNA aptamers to visualize IRE1α RNase activity in living cells

  • Optogenetic tools to spatiotemporally control IRE1α activation

• Cryo-electron tomography:

  • Visualize native IRE1α clusters in cellular membranes at near-atomic resolution

  • Map the 3D architecture of IRE1α signaling complexes in situ

• Spatial transcriptomics integration:

  • Combine IRE1α immunostaining with spatial transcriptomics to correlate IRE1α activation with local gene expression changes

  • Map XBP1 splicing and RIDD activity with subcellular resolution

These advanced techniques will enable researchers to address previously inaccessible questions about the spatial organization and temporal dynamics of IRE1α signaling complexes .

How might IRE1α antibodies be utilized in developing targeted therapeutics?

IRE1α antibodies have potential applications in therapeutic development:

• Target validation strategies:

  • Use antibodies to confirm IRE1α expression and activation in disease tissues

  • Correlate IRE1α activation patterns with response to experimental IRE1α inhibitors

  • Identify patient subpopulations with high IRE1α activity who might benefit from targeted therapy

• Companion diagnostic development:

  • Develop immunohistochemistry protocols using IRE1α antibodies to stratify patients for clinical trials

  • Create phospho-IRE1α assays as pharmacodynamic biomarkers to confirm target engagement

  • Establish multiplexed assays combining IRE1α with other UPR markers for comprehensive pathway assessment

• Antibody-drug conjugate potential:

  • Explore surface-accessible epitopes of IRE1α as potential targets for antibody-drug conjugates

  • Investigate cell-penetrating antibodies targeting the IRE1α kinase or RNase domains

  • Design bifunctional antibodies that simultaneously inhibit IRE1α and recruit immune effectors

• Combination therapy research:

  • Use antibodies to monitor IRE1α activity during combination treatments

  • For example, IRE1α inhibitors enhance anti-PD-1 immunotherapy in prostate cancer models

  • Identify synergistic pathways based on IRE1α activation patterns in response to treatment

Recent research demonstrates that targeting IRE1α can reprogram the tumor microenvironment and enhance immunotherapy, highlighting the importance of IRE1α as a therapeutic target in cancer .

What considerations are important when developing new IRE1α antibodies for specialized research applications?

Developing next-generation IRE1α antibodies requires:

• Epitope selection strategies:

  • Target conformational epitopes that distinguish between inactive and active IRE1α

  • Develop antibodies against oligomerization interfaces to selectively detect higher-order complexes

  • Generate antibodies against specific phosphorylation sites to monitor activation status

  • Consider antibodies that distinguish between human and mouse IRE1α for cross-species studies

• Validation approaches:

  • Validate in multiple systems including CRISPR knockout cells

  • Test specificity against IRE1β (the other IRE1 isoform) to ensure isoform selectivity

  • Validate functionality across multiple applications (WB, IP, IF, IHC, FACS)

  • Confirm detection of endogenous protein at physiological expression levels

• Application-specific considerations:

  • For live-cell imaging, develop non-neutralizing nanobodies that don't interfere with function

  • For therapeutics, focus on antibodies that can selectively modulate kinase or RNase activity

  • For structural studies, generate Fab fragments that stabilize specific conformations for crystallography

• Format innovations:

  • Develop recombinant antibodies with consistent performance across batches

  • Create bispecific antibodies targeting IRE1α and XBP1s for enhanced detection of the active pathway

  • Engineer antibody fragments optimized for super-resolution microscopy applications

The development of these specialized antibodies will enable more precise dissection of IRE1α biological functions and potentially lead to novel therapeutic approaches targeting specific aspects of IRE1α signaling .